Literature DB >> 23084848

Adjuvants in influenza vaccines.

Kohhei Tetsutani1, Ken J Ishii.   

Abstract

The effectiveness of influenza vaccines is still controversial, and the role of adjuvants in such vaccines is briefly reviewed in this paper. Inactivated whole virus vaccines may include components that function as adjuvants, meaning that additive adjuvants are often not required. MF59 and AS03 showed higher adjuvanticity than aluminum salts in several clinical studies. Recent research has suggested that immune cell recruitment is the main mechanism underlying adjuvant actions in general, and that aluminum salts induce this recruitment via inflammation at the injected site. The aspect of how oil-based adjuvants, such as MF59 and AS03, recruit immune cells remains to be clarified.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23084848     DOI: 10.1016/j.vaccine.2012.10.007

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Adjuvant effects of killed Lactobacillus casei DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice.

Authors:  Yu-Jin Jung; Ki-Hye Kim; Eun-Ju Ko; Youri Lee; Min-Chul Kim; Young-Tae Lee; Cheol-Hyun Kim; Subbiah Jeeva; Bo Ryoung Park; Sang-Moo Kang
Journal:  Vaccine       Date:  2020-07-13       Impact factor: 3.641

2.  Immunologic consequences of chemotherapy for ovarian cancer: impaired responses to the influenza vaccine.

Authors:  Christina S Chu; Jean D Boyer; Abbas Jawad; Kenyetta McDonald; Wade T Rogers; Eline T Luning Prak; Kathleen E Sullivan
Journal:  Vaccine       Date:  2013-09-13       Impact factor: 3.641

3.  Immunosenescence and novel vaccination strategies for the elderly.

Authors:  Michael G Dorrington; Dawn M E Bowdish
Journal:  Front Immunol       Date:  2013-06-28       Impact factor: 7.561

4.  Complete Protection against Influenza Virus H1N1 Strain A/PR/8/34 Challenge in Mice Immunized with Non-Adjuvanted Novirhabdovirus Vaccines.

Authors:  Ronan N Rouxel; Emilie Mérour; Stéphane Biacchesi; Michel Brémont
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

5.  Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence.

Authors:  Megan K L Macleod; Alexandria David; Niyun Jin; Laura Noges; Jieru Wang; John W Kappler; Philippa Marrack
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

Review 6.  Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head.

Authors:  Lidewij C M Wiersma; Guus F Rimmelzwaan; Rory D de Vries
Journal:  Vaccines (Basel)       Date:  2015-03-26

Review 7.  Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Authors:  Elke S Bergmann-Leitner; Wolfgang W Leitner
Journal:  Vaccines (Basel)       Date:  2014-04-10

Review 8.  Influenza vaccines: unmet needs and recent developments.

Authors:  Ji Yun Noh; Woo Joo Kim
Journal:  Infect Chemother       Date:  2013-12-27

Review 9.  Influenza vaccines: a moving interdisciplinary field.

Authors:  Michael Schotsaert; Adolfo García-Sastre
Journal:  Viruses       Date:  2014-10-09       Impact factor: 5.048

10.  Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.

Authors:  Niels Peter H Knudsen; Anja Olsen; Cecilia Buonsanti; Frank Follmann; Yuan Zhang; Rhea N Coler; Christopher B Fox; Andreas Meinke; Ugo D'Oro; Daniele Casini; Alessandra Bonci; Rolf Billeskov; Ennio De Gregorio; Rino Rappuoli; Ali M Harandi; Peter Andersen; Else Marie Agger
Journal:  Sci Rep       Date:  2016-01-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.